Introduction {#s001}
============

Postinfectious diffuse pulmonary disease with chronic lung impairment has traditionally been associated with classic postinfectious bronchiolitis obliterans (PIBO), which is an obstructive lung disease, leading to partial or complete small airway occlusion, sometimes occurring in children following a severe lower respiratory tract infection.^[@B1]^

Clinical diagnosis of classic PIBO is based on the persistence of tachypnea, wheezing, and/or hypoxemia for at least 6 weeks following severe bronchiolitis or pneumonia. Characteristic radiological findings include air trapping, hyperinflation, mosaic pattern, bronchial wall thickening, and bronchiectasis, and pulmonary function testing reveals obstructive lung function.^[@B1],[@B4],[@B5]^ The diagnosis is histopathologically characterized by a distinctive pattern of peribronchiolar fibrosis that ultimately results in complete obliteration of the bronchiolar lumen.^[@B1]^

Treatment options are limited and based on empirical evidence and these therapies reportedly yield disappointing responses, and affected children show a high persisting morbidity rate.^[@B1],[@B6]^ However, long-term data and prognostic information are limited to a few case series, none of which focuses on peripheral airway impairment and physical ability, and are mainly focused on the classical form of PIBO and not a broader spectrum of postinfectious diffuse pulmonary disease mimicking other severe diffuse lung diseases.^[@B7]^ Such children may have less severe chronic intractable disease although phenotypical characteristics similar to patients with classic pathohistological pattern of PIBO.

Our aim was to investigate detailed clinical and pathohistological characteristics at baseline and perform comprehensive assessment of pulmonary function and fitness at follow-up in a cohort of children with chronic postinfectious diffuse pulmonary disease in a broader term to estimate long-term pulmonary impairment and monitor changes over time. We hypothesized that spirometry values would remain severely impaired, showing an obstructive pattern and that lung clearance index (LCI~2.5~) and peak oxygen uptake (VO~2peak~) would show diminished values, while diffusing capacity (DLco) and physical exertion would likely be unaffected.

Materials and Methods {#s002}
=====================

Study design and patient population {#s003}
-----------------------------------

This descriptive, single-center follow-up study included children and young adults with a biopsy-verified diagnosis of postinfectious diffuse pulmonary disease according to criteria listed below. Cases were retrieved from the local database and by searching the Discharge Register of Copenhagen University Hospital (Rigshospitalet). The search was limited to cases with onset \<16 years of age, registered between January 1998 and December 2015.

Patients who had completed their primary treatment course and were continued on medication---such as hydrocortisone substitution, inhaled asthma medication, (bronchodilators and corticosteroids) or azithromycin---were eligible to participate in the follow-up part consisting of one study visit. The visit was postponed for at least 2 weeks in case of respiratory tract infection within the past 14 days. Exclusion criteria were reduced ability to provide informed consent and inability to cooperate to spirometry or nitrogen multiple-breath washout (N~2~MBW).

Retrospective data {#s004}
------------------

The clinical diagnostic criteria for inclusion were a combination of the following: history of severe infection (pneumonia/bronchiolitis); clinical features associated with diffuse lung disease (tachypnea, wheezing, and/or hypoxemia) persisting at least 6 weeks; characteristic high resolution computed tomography (HRCT) findings (air trapping, hyperinflation, and mosaic pattern); and lung biopsy excluding other diffuse lung diseases, such as neuroendocrine hyperplasia of infancy (NEHI), pulmonary interstitial glycogenosis (PIG), surfactant disorders, or other well-known pathohistological entities within children\'s interstitial lung diseases.^[@B11]^ Electron microscopy of lung biopsy material and analysis of inflammatory cells in bronchoalveolar lavage (BAL) fluid were sometimes performed although not part of the routine workup.

Significant immunodeficiency was excluded by basic screening, including white blood cell counts, immunoglobulins and subclasses, and mannose-binding lectin (MBL). Selected cases were subjected to an extended workup that included lymphocyte marker analysis, complement, and somatic hypermutation.

Previous pulmonary measurements were retrieved from the hospital database.

As this was not a controlled prospective study, no specified treatment protocol was applied. Treatment regimens were individualized and based on predominant symptoms and disease severity.

Follow-up visit {#s005}
---------------

### Pulmonary function and exercise tests {#s006}

N~2~MBW was performed using Exhalyzer D (Eco Medics AG, Duernten, Switzerland) and its associated software (Spiroware 3.1.6 ext., Eco Medics AG),^[@B12]^ and LCI~2.5~ was the primary outcome. LCI~2.5~, S~cond~, and S~acin~ (Scond and Sacin are indices of ventilation heterogeneity in the conductive and acinar lung zones) were measured in accordance with the consensus statement of the European Respiratory Society (ERS)/American Thoracic Society (ATS).^[@B13],[@B14]^ For each patient, the mean LCI~2.5~ from three runs of N~2~MBW measurements was used for analysis. Spirometry, diffusing capacity (DLco), and body plethysmography were performed using Jaeger Master Screen Pro (Carefusion, Hochberg, Germany) according to ATS and ERS recommendations.^[@B15]^ Bronchodilator responsiveness (BDR) was assessed using 400 μg inhaled salbutamol, and significant BDR was defined as ≥12% increase in forced expiratory volume in 1 second (FEV~1~).^[@B19]^

Fitness in terms of peak oxygen uptake (VO~2peak~) was assessed during an incremental exercise test on an electronically braked cycle ergometer, as previously described.^[@B20]^

A more detailed description of pulmonary function testing and exercise testing is available online ([Supplementary Data S1](#SD1){ref-type="supplementary-material"}).

### Questionnaire {#s007}

We created a short questionnaire covering various respiratory symptoms and physical activity limitations. The questions were related to the past 2 weeks before the visit. Description of the design of the questionnaire and the questionnaire is available online ([Supplementary Data S1](#SD1){ref-type="supplementary-material"} and [S2](#SD2){ref-type="supplementary-material"}).

Statistics {#s008}
----------

Statistical analysis was performed using MedCalc Version 16.2.1 (MedCalc Software, Mariakerke, Belgium). Follow-up data were compared to baseline using paired *t*-test. Lower limit of normal (LLN) were defined as a *z*-score \<−1.64 (spirometry, diffusing capacity, and VO~2peak~), and upper limit of normal (ULN) was defined as *z*-score \>1.64 (LCI~2.5~). Linear regression was performed for continuous parameters. *P*-value \<0.05 was considered statistically significant. Covariates found to be significant in univariate analysis were included in multiple linear regression analysis, with stepwise forward and backward selection to analyze how N~2~MBW indices and VO~2peak~ were related to other parameters.

Ethics {#s009}
------

This study was approved by the Research Ethics Committee of the Capital Region of Denmark (J. no. H-4-2013-154) and the Danish Data Protection Agency (J. no. 30--1142, ID no. 02838). Written informed consent was obtained from patients \>18 years and from the legal guardians of all participants \<18 years.

Results {#s010}
=======

Characteristics of all patients {#s011}
-------------------------------

Thirty patients fulfilled the inclusion criteria. None of the patients suffered from any comorbidity such as cardiac, metabolic, or neurological disease. Twenty-eight patients were born at term, one at gestational age (GA) of 33, and one at GA of 35 weeks. Four had mild respiratory distress syndrome (including the child with a GA of 33 weeks). The mean birth weight (range) was 3.407 kg (1.676--5.050). Twenty-nine patients had completed treatment and 25 were eligible for the follow-up analysis. Seventeen patients consented to participate in the follow-up study, but two were not able to cooperate to the tests ([Fig. 1](#f1){ref-type="fig"}).

![Flow diagram of the inclusion and study process of children and young adults with postinfectious diffuse pulmonary disease (PIDPD).](fig-1){#f1}

Retrospective data {#s012}
------------------

The median (range) age at onset of persistent respiratory symptoms in the initial cohort of 30 patients was 4.5 (0--170 months) and the median age at diagnosis was 27.5 (2--172) months. Hence, mean lag time of diagnosis was 23 months. Only 36.7% were diagnosed within 6 months of symptom onset ([Supplementary Fig. S1](#SD3){ref-type="supplementary-material"}). Before diagnosis, 26.7% were treated with macrolides, 70% with other antibiotics, 76.7% with beta~2~-agonists, 66.7% with inhaled corticosteroids, and 30% with oral corticosteroids. [Table 1](#T1){ref-type="table"} outlines the baseline characteristics of patients at first visit.

###### 

Clinical Characteristics at Diagnosis

  ------------------------------------------------------------- ---------------------
  *N*                                                           30
  Gender (M/F)                                                  17/13
  Dyspnea during activity/play/exercise                         73.3%
  Cough                                                         50.0%
  Failure to thrive (weight SD \< −1.96)                        23.3%
  Fever                                                         6.7%
  Wheeze                                                        40.0%
  Tachypnea                                                     66.6%
  Weight (SD), mean (range)                                     −0.95 (−2.5 to 1.3)
  Height (SD), mean (range)                                     −0.55 (−2.0 to 1.4)
  Crackles                                                      56.7%
  Binasal cath oxygen supplementation                           23.3%
  Clubbing                                                      10%
  Age at onset (months), mean (range), *n* = 30                 4.5 (0--170)
  Age at diagnosis (months), mean (range), *n* = 30             27.5 (2--172)
  Age at the end of treatment (years), mean (range), *n* = 30   6.5 (1--16.3)
  Age at follow-up (years), mean (range), *n* = 15              13.0 (5.6--27.5)
  Follow-up time (years), mean (range), *n* = 15                7.6 (2--15)
  ------------------------------------------------------------- ---------------------

SD, standard deviation.

At diagnosis, all but two patients were investigated with HRCT. The most frequent findings were bronchiectasis (42.9%), mosaic perfusion (60.7%), atelectasis (39.3%), and air trapping (42.9%). Echocardiography was performed in 66.7%. Pulmonary hypertension indicated by a tricuspid insufficiency gradient \>30 mmHg was found in 15%.

Microbiological assessments of samples from laryngeal swabs or BAL at onset were available from 80% of children of whom 13% had negative findings. A wide range of bacteria and viruses were isolated, but the most frequent findings were *H. influenzae* (16.7%) and rhinovirus (10%). Details are further outlined online ([Supplementary Fig. S2](#SD4){ref-type="supplementary-material"}).

All children underwent lung biopsies, predominantly as open lung biopsy procedures (93.3%). Histology data were missing in 3.4% (*n* = 1). The overall lung parenchyma architecture was generally preserved, with distortion being mild in 93.3% of patients, moderate in 6.7%, and severe in 0%. Centrilobular and interstitial inflammatory cell infiltrates predominantly comprised CD3^+^/CD4^+^ T lymphocytes. Chronic inflammatory cell infiltrates were primarily located in the interstitium in 50% of patients and showed peribronchiolar distribution in 46.7%. Varying degrees of follicular aggregates of CD20^+^ B lymphocytes or reactive germinal center arrangements around the bronchioles were seen in 12 cases (40%). One child (3.4%) showed moderate interstitial fibrosis, 10 children (34.5%) showed minor fibrous thickening of alveolar walls, and 19 (65.5%) showed no interstitial fibrosis. Acute or granulomatous inflammation, hyaline membranes, necrotic debris, and foreign material were not observed, and no biopsies showed exclusively classic features seen in PIBO.

Basic screening for latent immunodeficiency was performed in 90% of patients at diagnosis. Two children exhibited slightly decreased IgG, which was not considered clinically relevant and thus no substitution therapy was required. Extended immune system evaluation was conducted in 86.7% of the cohort, revealing no major abnormalities. A genotype related to impaired MBL function was found in 10 children (∼30%). No children were considered to show clinically significant relevant immunoincompetence.

Although treatment varied, all patients received monthly intravenous high-dose pulse methylprednisolone (*n* = 30). Some cases were also administered oral prednisolone, hydroxychloroquine, azathioprine, mycophenolate mofetil, or cyclosporine due to disease severity and insufficient treatment response ([Supplementary Table S1](#SD5){ref-type="supplementary-material"}).

Patients eligible for follow-up {#s013}
-------------------------------

The mean period between end of treatment and follow-up in 15 patients lasted 7.6 years. Age at onset, diagnosis, and end of treatment is shown in [Table 1](#T1){ref-type="table"}.

### Pulmonary function {#s014}

LCI~2.5~, S~cond~, and S~acin~ were abnormal in 80%, 73%, and 80% of cases. FEV~1~ was abnormal in 53%, median *z*-score −1.9. FEV1/FVC median (range) was 0.82 (0.4--1.0) and was abnormal in 47%, thus indicating an obstructive pattern. Significant BDR was shown in 33.3%. [Table 2](#T2){ref-type="table"} shows additional pulmonary function results.

###### 

Pulmonary Function at Follow-Up in 15 Patients

  *Lung function test*              *Abnormal (%)*   z*-score median (range)*   *% Predicted median (range)*   *Absolute values median (range)*
  --------------------------------- ---------------- -------------------------- ------------------------------ ----------------------------------
  N~2~ MBW (*N* = 15)                                                                                          
   LCI~2.5~                         80.0             10.0 (0.5 to 20.1)         163 (102--372)                 10.60 (6.80--24.30)
   S~cond~                          73.3             2.5 (−5.0 to 10.3)         150 (50--700)                  0.025 (0.007--0.14)
   S~acin~                          80.0             4.0 (−0.8 to 7.6)          317 (83--1100)                 0.17 (0.048--0.58)
  Spirometry (*N* = 15)                                                                                        
   FEV~1~, L                        47.0             −1.9 (−5.8 to 0.0)         78 (27--100)                   2.00 (0.80--4.60)
   FVC, L                           20.0             −1.0 (−3.7 to 1.1)         87 (58--113)                   2.53 (0.85--6.01)
   MMEF 72 to 75, L/s               46.7             −1.5 (−6.5 to 0.4)         71 (8--109)                    1.61 (0.30--5.07)
   FEV~1~/FVC, ratio                47.0             −0.3 (−4.7 to 1.7)         98 (46--108)                   0.82 (0.40--0.90)
  Diffusing capacity (*N* = 15)                                                                                
   DL~CO~, mmol/min/kPa             13.3             0.4 (−3.9; 5.1)            107 (55,213)                   6.9 (4.2--13.9)
   DL~CO~/V~A~, mmol/min/kPa/L      6.7              0.0 (−0.7; 4; 7)           100 (88--180)                  1.9 (1.6--3.3)
  Body plethysmography (*N* = 15)                                                                              
   RV, L                            26.7             2.3 (−0.3 to 4.7)          134 (47--238)                  2.66 (0.53--6.38)
   TLC, L                           40.0             −0.1 (−5.5 to 2.2)         99 (44--122)                   1.47 (0.47--3,39)
   VC, L                            60.0             −2.8 (−5.7 to 4.1)         68 (36--145)                   4.15 (1.30--9.87)
   RV/TLC ratio                     46.7             1.8 (0.1 to 5.4)           144 (103--234)                 0.35 (0.25--0.7)

DL~CO~, single breath diffusing capacity of the lung for carbon monoxide. DL~CO~/VA, diffusion capacity corrected for Alveolar volume; FEF~25--75~, forced mid expiratory flow; FEV~1~, forced expiratory volume in 1 s. FVC, forced vital capacity; LCI, Lung Clearance Index; MBW, N~2~, nitrogen multiple-breath washout; RV, residual volume; S~acin~, Acinar airways ventilatory heterogeneity; S~cond~, conductive airways ventilatory heterogeneity; TLC, total lung capacity; VC, vital capacity.

Longitudinal lung function data (range: 2--15 years) were additionally available in 14/30 children ([Fig. 1](#f1){ref-type="fig"}). Individual trend curves of zFEV~1~, zFVC, and zFEV~1~/FVC are illustrated online ([Supplementary Fig. S3](#SD6){ref-type="supplementary-material"}). All longitudinally assessed lung function parameters remained unchanged throughout follow-up after completion of treatment ([Table 3](#T3){ref-type="table"}).

###### 

Longitudinally Assessed Parameters From End of Treatment Until Last Follow-Up Visit (Mean Follow-Up Period of 6.2 Years)

  N* = 14*      *End of treatment, median (range)*   *Last visit, median (range)*   *Paired* T*-test*
  ------------- ------------------------------------ ------------------------------ -------------------
  zFEV~1~       −2.64 (−5.73 to 1.69)                −2.72 (−6.17 to 0.38)          *P* = 0.83
  zFVC          −1.34 (−3.07 to 1.37)                −1.15 (−3.70 to 0.65)          *P* = 0.86
  zFEV~1~/FVC   −1.89 (−4.65 to 1.94)                −1.53 (−5.02 to 0.50)          *P* = 0.82

FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity.

### Exercise testing {#s015}

[Table 4](#T4){ref-type="table"} presents the exercise test results. All subjects met the peak exercise criteria, except one patient who could only complete a test duration of 5 min, and one patient who could not cooperate due to young age (5 years). One patient showed abnormal VO~2peak~ (zVO~2peak~ = −2.1), but all other parameters were normal, and the patient was not considered limited by respiratory conditions. One patient exhibited desaturation (SpO~2~ \< 90%) during the last 90 s. This patient had an increased LCI~2.5~ (13.4), abnormal zFEV~1~/FVC ratio (−2.48), and a zVO~2peak~ in the lower normal range (−1.45), but all other lung function parameters were normal.

###### 

Peak Oxygen Uptake Results in 13 Patients

                                      *Median*   *Range*
  ----------------------------------- ---------- -------------
  VO~2peak~, mL/kg/min                42.5       32.3--53.4
  VO~2peak~, mL/kg/min, % predicted   89.6       69.9--115.6
  VO~2peak~, mL/kg/min, *z*-scores    −0.77      −2.1--1.1
  V~E~, L/min (BTPS)                  61.4       43.2--156.0
  RF, min^−1^                         48.9       20.4--77.3
  RER                                 1.15       1.1--2.6
  HR~max~, bpm                        191        176--210
  Min. S~pO2~, %                      95         83--99
  Test duration, min                  7          5--11
  W~max~, watt                        160        50--350
  W~max/kg~                           3.7        2.5--4.7
  V~E~/V~CO2~, %                      29.8       21.8--50.5

HR~max~, maximal heart rate; Min S~p~O~2~, oxygen saturation; RER, respiratory exchange ratio; RF, respiratory frequency; V~E~, peak minute ventilation; V~E~/VCO~2~, ventilatory equivalent for CO~2~; VO~2peak~, peak oxygen uptake; W~max~, maximal work load.

Linear regression revealed no significant association between zVO~2peak~ and any pulmonary function parameters. The final multiple linear regression model (adjusted *R*^2^ = 0.61) confirmed a significant association between zLCI~2.5~ and zFEV~1~ (*P* = 0.0005).

Self-reported respiratory symptoms and activity level {#s016}
-----------------------------------------------------

Among patients who reported "feeling breathless," the majority mentioned sports and heavy play activities as primary triggers (87%). Difficulties during these activities were reported by 40%, while 53% had no respiratory difficulties during physical exercise. However, most subjects were physically active; 53% for 5--7 h in an average week, and 27% for 3--4 h/week ([Supplementary Data S3](#SD7){ref-type="supplementary-material"}).

Discussion {#s017}
==========

The present results demonstrated chronic lung function impairment in our cohort of children diagnosed with postinfectious diffuse pulmonary disease documented by varying degree of both bronchiolar and/or interstitial/alveolar histological abnormalities in lung biopsy and structural changes on HRCT. Most cases had onset very early in life with considerable heterogenous microbiological pathogens and varying lag time until diagnosis. Patients with longitudinal data and/or eligible for follow-up exhibited persistent abnormal spirometry and abnormal N~2~MBW indices many years after the initial infectious injury. Despite airway impairment, these children generally showed overall physical ability (estimated by VO~2peak~) within the normal range and had a preserved diffusion capacity. Moreover, based on this small cohort of patients with postinfectious diffuse pulmonary disease, the lung condition did not seem to be progressive, as spirometry results were unchanged many years after completion of treatment. Our findings confirmed that postinfectious diffuse pulmonary disease histopathologically is a heterogenous and severe chronic lung condition, characterized by persistent pulmonary impairment (especially peripheral). However, the cohort showed acceptable overall fitness despite 40% reported feeling breathless playing sports or games.

To our knowledge, this is the first study presenting N~2~MBW and VO~2peak~ data from a cohort with diffuse lung disease categorized as postinfectious diffuse pulmonary disease in a broader term and not just classical PIBO. Colom et al. performed a prospective long-term follow-up study on pulmonary function in a pediatric cohort (*n* = 46) with classic PIBO.^[@B7]^ As in our study, they reported severely impaired pulmonary function after a 12-year follow-up period. In contrast to our findings of stable lung function, Cazzato et al. reported decline by 1% per year in FEV~1~, FVC, and FEV~1~/FVC over a median follow-up time of 10 years in a study of children with classic PIBO.^[@B10]^ It is not possible to explain this contrast in results, but it may be caused by heterogenous patient populations, small sample sizes in both studies (11 in the study by Cazzato et al. and 30 in our study), and different treatment regimens and durations. Mattiello et al. reported VO~2peak~ in 20 children with PIBO.^[@B21]^ Mean age in this group was 11 years with no information of clinical condition or medical treatment. Mean (standard deviation) VO~2peak~ was 77.5% versus 89.6% in our population. In contrast to our study, they reported a reduced VO~2peak~ (\<85% predicted) in 11 (55%) patients. The patients included in our study had completed their primary treatment course, but it is uncertain whether this applies for the included patients in the study by Mattiello et al., which may explain the higher level of abnormal values.

N~2~MBW outcomes are more frequently abnormal than FEV~1~, and N~2~MBW is likely more sensitive than spirometry as marker of significant distal airway involvement in lung diseases. This has been demonstrated in children with primary cilia dyskinesia, hypersensitivity pneumonitis, cystic fibrosis, and in children experiencing allograft rejection after human stem cell transplantation.^[@B20],[@B22]^ Compared to hypersensitivity pneumonitis, these children with postinfectious diffuse pulmonary disease was dominated by more severely affected N~2~MBW indices and lower zFEV~1~. Despite the greater obstructive pattern in lung function, only a minority of this cohort showed VO~2peak~, similar to the findings in the hypersensitivity pneumonitis cohort.^[@B22]^ Low VO~2peak~ may reflect several different physical limitations that are not exclusively related to lung disease.^[@B25]^ One patient had abnormally low VO~2peak~, as well as impaired LCI~2.5~, DLco/VA, and total lung capacity. However, this patient reported that he participated in physical activities without difficulty and was physically active 5--7 h a week; therefore, we documented no respiratory limitation. This indicates that remarkable overall compensation may be possible and is supported by the finding that the majority of children had only minor subjective respiratory complaints in daily life---apart from "feeling breathless" upon heavy physical exercise, which is commonly reported also by healthy children.

Classic PIBO is a rare disease that has been mainly studied in South America where adenovirus is the predominant cause.^[@B7],[@B8],[@B26],[@B27]^ In contrast, adenovirus was a possible causative agent in only 7% (*n* = 2) of our patient cohort. This difference is likely due to the high prevalence of viral disease in South America, and the lower socioeconomic status, which is related to poor sanitation, lower hygienic practices, indoor smoking, and overcrowding, all of which contribute to facilitating adenovirus transmission.^[@B1],[@B28]^ In our cohort, the possible causative infectious agents were reported as contemporary microbiological findings and sometimes of speculative relevance and could thus be considered trivial and not classic infections able to cause chronic lung disease. Therefore, the exact cause of pulmonary disease, although highly likely of infectious nature, was not always elucidated by accessible tests. However, the majority of patients was considered chronically affected with abnormally reduced FEV~1~ in more than 50% of patients and increased LCI in 80%. The duration of time from end of treatment to follow-up visit varies from 2 to 15 years, and therefore, it should be acknowledged that children with shortest follow-up could potentially recover.

Diagnosis of postinfectious diffuse pulmonary disease can be challenging, since it may clinically resemble other diffuse lung diseases, especially in infants and preschool children, with a wide spectrum of severity.

Our present findings support the existence of a disease entity with some diagnostic ambiguity. In many cases, adenovirus or other microbiological agents are not documented, and lung function cannot be assessed due to the young age of onset may be an option IT WAS not available. Furthermore, many of these children show phenotypic overlap with "persistent tachypnea of infancy" or other diseases seen in infancy, such as NEHI and PIG. In unclear cases, HRCT may be useful to exclude other diffuse lung diseases.

Some confusion exists regarding the terminology used for bronchiolar disorders. The basic "injury" may be caused by several factors other than infections, including connective tissue diseases and allograft rejections, and often shows nonspecific histological features regarding etiology.^[@B29]^ PIBO is primarily considered an entity with a constrictive pattern, and is pathologically characterized by a distinctive pattern of peribronchiolar fibrosis that ultimately results in complete obliteration of the bronchiolar lumen.^[@B1]^ However, our cohort did not exhibit this classic histological pattern, and was instead dominated by signs of follicular bronchiolitis. It is unclear whether this is related to early milder stage of PIBO or something different.

After infection, most healthy children undergo total recovery, including "repair" of the lung epithelial surface area. However, in some children, the repair process seems to fail. In such cases, the final fibrotic remodeling process may result from complex interactions between epithelial and mesenchymal cells, imbalanced production of mediators and growth factors, and local mitogenic factors due to prolonged denudation of the basement membrane after injury.^[@B30]^ This process can potentially be altered or stopped, yielding a varying degree of histopathological changes, as seen in our cohort. Thus, the term postinfectious diffuse pulmonary disease might be a better term to reflect the spectrum of disease severity and would encompass a spectrum of changes from mild airway injury with only mild peribronchiolar or interstitial inflammation (as seen in our cohort) to severe airway fibrosis with significant luminal narrowing and to complete airway obliteration. However, further studies with detailed histological focus are needed to subgroup these children, which is difficult in this study as it covered almost two decades with loss or damage to some of the original histological slides.

Strengths of our study include the detailed description of our cohort, and the long follow-up period, including long-term longitudinal data. We investigated a unique cohort of children having a documented clinical history and diagnosis involving open lung biopsy and HRCT. Moreover, we included a panel of different advanced pulmonary function parameters, along with peak oxygen uptake, thus covering different aspects of airway function and overall physical fitness.

The primary limitation of this study is the small number of patients participating and the long timespan of diagnosis (1998--2015). Both limitations are often inevitable in research regarding rare diseases and lack of power to discover changes over time is a risk. Despite the long timespan, the overall basic diagnostic methods and treatment regimens have not been changed dramatically, although knowledge of diffuse lung diseases in children have increased significantly over the last 10 years---both clinically and in terms of histopathology. Additional inflammatory BAL profiles would have improved the study. Moreover, selection bias cannot be excluded since the follow-up study included only 50% of the entire cohort for different reasons. We also included two mild ex-premature patients who may have introduced other aspects of pulmonary disease not related to a postinfectious condition, but without history of bronchopulmonary dysplasia and therefore not considered clinically relevant.

Some of the cases were diagnosed many years ago, so it cannot be excluded that some represent NEHI, which is a relatively new diagnostic entity and requires special bombesin staining.^[@B31]^ However, this was not supported by clinical history, HRCT or histopathology. Open lung biopsy was performed in 93% of the patients. All lung biopsies include a risk of false negative results due to patchy distribution of structural changes, including postinfectious changes, but we consider this risk to be limited since all biopsies were guided by HRCT-documented structural abnormalities, and open lung biopsies in general provide a larger tissue yield. The severity of the biopsy findings was graded according to the subjective judgment of the pathologists since no clear objective classification exists, although such a system would have improved the study by a rereview of all the slides. However, some of the slides had age-related damage or were lost (*n* = 7). Another limitation is the use of a nonvalidated questionnaire to assess physical limitations and weekly physical activity and the lack of a healthy reference group for comparison. Rather than providing information about physical activity in general, the questions were related to the last 2 weeks; however, the results seem acceptable as they were correlated with the contemporary lung function data acquired at the follow-up visit. During the study period, no validated child-specific quality-of-life questionnaire was available, but this is currently under consideration within the child-EU project.^[@B32]^

Previous N~2~MBW measurements were unavailable; thus, we could not evaluate the development of N~2~MBW indices over time. Future studies should evaluate the use of N~2~MBW measurements for monitoring treatment effects and evolution in diffuse lung disease as demonstrated in previous studies from our center.^[@B20],[@B23],[@B33]^

The present study was focused on long-term follow-up and prognosis after treatment completion. The aim was not to evaluate specific individual treatment responses. Future studies are needed to investigate this aspect, especially in terms of the correlation to individual histopathological findings in surgical lung biopsy specimens. It would certainly be interesting to evaluate whether a "window of opportunity" exists, during which a failed and disorganized "repair track" can be altered or stopped to prevent irreversible lung damage, which carries a reported mortality rate of up to 18% during the acute phase in PIBO.^[@B1],[@B8]^

Although our results revealed significant peripheral airway impairment below normal values, it did not seem to affect physical ability during follow-up. However, the subsequent natural decline in adulthood may lead to early development of a severe condition resembling COPD, which is similar to speculations concerning bronchopulmonary dysplasia.^[@B34]^

Conclusion {#s018}
==========

Postinfectious diffuse pulmonary disease in children carries a varying degree of chronic pulmonary impairment with onset of symptoms in the first months of life and a typical considerable lag time before diagnosis. Follow-up of several years after the initial injury demonstrated moderate-to-severe peripheral airway impairment although no further lung function decline was found after completion of treatment. Despite acceptable VO~2peak~, a considerable proportion struggled during heavy exercise.

These findings support that the term postinfectious diffuse pulmonary disease covers a broader spectrum that do not seem to meet the criteria for the classical and more severe PIBO entity, but still represent significant chronic pulmonary impairment. There remains a need for further larger and possibly multicenter studies regarding early treatment intervention and continuous follow-up into adulthood to estimate the true long-term prognosis. Our study precedes newly initiated European strategies to fulfil such goals.^[@B33]^
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